Adnexal Diseases  >>  sunitinib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sunitinib / Generic mfg.
NCT00388037: Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed
2
31
Canada
sunitinib malate, SU11248, sunitinib, Sutent, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
01/12
01/12
NCT00768144: Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Completed
2
36
US
Sunitinib, Sutent
Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
05/12
02/13
NCT00543049: Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

Checkmark P2 data
Mar 2012 - Mar 2012: P2 data
Completed
2
73
Europe
Sunitinib, Sutent, Sunitinib, SU011248, SUNITINIB, SUTENT, Sunitinib, SU011248
AGO Study Group, Philipps University Marburg Medical Center, HSK Reasearch GmbH Wiesbaden
Platinum Refractory Epithelial Ovarian Cancer, Primary Cancer of the Peritoneum, Cancer of the Fallopian Tube
06/12
 
NCT01824615: Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Completed
2
30
RoW
Sunitinib, Sutent
Cathay General Hospital
Ovarian Cancer, Adverse Effects
01/16
01/16

Download Options